Search Bar & Filters
Found 50 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.
Actively Recruiting
Researchers are evaluating BG-C137, an antibody-drug conjugate targeting FGFR2b, in people with advanced solid tumors. This study aims to assess the safety, tolerability, how the drug moves and acts in the body, and early antitumor effects. It is a phase 1ab trial involving participants with tumors expressing FGFR2b or FGFR2 gene amplification who have received prior cancer treatments. The study is sponsored by BeOne Medicines and includes two main phases dose escalation and dose expansion. The trial has three parts Phase 1a evaluates increasing doses of BG-C137 alone and then in combination with other anticancer agents to establish safe dose levels. Phase 1b further explores the recommended dose in selected patient groups. BG-C137 and anticancer agents are given intravenously or orally depending on the treatment. Participants undergo dose escalation, safety expansions, and dose confirmations to determine the best dosing for further study. Participants will be monitored regularly for side effects and response to treatment for up to about two years. Assessments include measuring adverse events, drug levels in the blood, tumor response, and immune reactions to the drug. Safety follow-up visits occur after treatment ends. Researchers will measure outcomes such as maximum tolerated dose, overall response rate, disease control, and progression-free survival. The trial involves frequent visits for treatment and assessments throughout the study period.
Actively Recruiting
This trial investigates BG-85738, a new experimental drug, in adults with advanced or metastatic solid tumors that have mutations in the RAS gene. It aims to evaluate the safety and effects of BG-85738 alone and in combination with other anticancer agents in patients whose cancer involves uncontrolled growth due to hyperactive RAS proteins. The study is conducted in two parts dose escalation to identify safe dosage levels, and dose expansion to study the drugs effects in more patients. Participants receive BG-85738 orally either by itself or combined with intravenous drugs tislelizumab or cetuximab. The dose escalation part tests ascending doses to find recommended levels without serious side effects. The dose expansion part treats participants with selected tumor types using the doses identified earlier, either as monotherapy or in combination with the other agents. The study involves multiple centers worldwide. Participants will visit clinics regularly over approximately 13 to 24 months for treatments and health monitoring. Assessments include blood tests, tumor imaging, and safety evaluations to track adverse events and drug effects. Researchers will measure outcomes such as response rates, progression-free survival, and drug levels over time. Safety is monitored up to 30 days after treatment ends, with ongoing follow-up to assess treatment impact and tolerability.
Actively Recruiting
Researchers are evaluating the safety, tolerability, pharmacokinetics, and early antitumor activity of the drug BG-C0979 alone or combined with tislelizumab in adults with certain advanced solid tumors. This first-in-human study includes Phase 1a, focusing on dose escalation and safety expansion, and Phase 1b, which involves dose optimization and expansion. The study is sponsored by BeOne Medicines and aims to find safe and effective doses for future research. Participants will receive BG-C0979 through intravenous infusion. In Phase 1a, doses are gradually increased to find safe levels, followed by safety expansion at selected doses. In Phase 1b, participants receive optimized doses of BG-C0979 alone or in combination with tislelizumab for selected tumor types. The study includes multiple treatment groups, each with specific dosing plans and evaluation periods lasting up to approximately 24 months. During the study, participants will undergo regular assessments including imaging to measure tumor response, laboratory tests, and monitoring of side effects. Researchers will track drug levels in blood and evaluate measures like overall response rate, duration of response, disease control rate, and progression-free survival. This comprehensive monitoring will continue for up to two years to evaluate safety and preliminary effectiveness of the treatments.
Actively Recruiting
Open-label Dose-Escalation Study of Oral D3S-003 for Advanced Solid Tumors with KRAS p.G12D Mutation
Researchers are evaluating D3S-003, an oral drug, in a first-in-human Phase 1 clinical trial for participants with advanced solid tumors that have a specific KRAS p.G12D mutation. This trial aims to assess the safety, tolerability, how the drug is processed by the body, its biological effects, and early signs of how well it might work. Participants must have cancers that have not responded to standard treatments or have no effective standard options, and tumors that can be measured by imaging. The study includes two parts of dose escalation to find the best dosing schedule once daily and twice daily dosing of D3S-003. Participants will receive the drug orally with doses gradually increased to evaluate safety and identify the maximum tolerated dose and recommended Phase 2 dose. The treatment period can last up to approximately seven months or until disease progression or unacceptable side effects occur. During the study, participants will have regular monitoring for side effects and safety from the screening visit until 30 days after the last dose. Researchers will measure drug levels in the blood and evaluate tumor response using standardized criteria. The primary outcomes include the number of participants experiencing dose-limiting toxicities and adverse events. The trial will last until January 2028, with frequent assessments during treatment cycles of 21 days each.
Actively Recruiting
Researchers are investigating treatments for people with advanced solid tumors that have a specific genetic mutation called KRASG12C. The study focuses on evaluating a new drug, BAY3498264, which targets the SOS1 protein that interacts with KRAS, alongside an existing approved drug called sotorasib. This first-in-human study aims to find out how safe BAY3498264 is when combined with sotorasib and to determine the highest safe dose of BAY3498264 in this combination. Participants will receive BAY3498264 alone for the first seven days, followed by cycles of 21 days where they take BAY3498264 together with daily sotorasib. The study has three parts dose escalation to find the right dose, backfill cohorts to gather additional safety and drug data, and exploratory expansion cohorts to further assess safety and effectiveness. Treatment continues as long as it remains beneficial without severe problems or until the cancer progresses. Throughout the study, researchers will collect blood and urine samples, perform imaging scans such as CT, PET, MRI, and X-rays, and monitor heart health using electrocardiograms. They will track side effects, drug levels in the blood, and tumor responses regularly. Participant health is closely monitored during treatment, and safety is assessed up to about 30 to 35 days after the last dose, with the whole study expected to last approximately three years.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of AMO959 combined with lutetium 177Lu vipivotide tetraxetan AAA617 and androgen receptor pathway inhibitors ARPIs in adult men with PSMA-positive metastatic castration resistant prostate cancer mCRPC. This study includes participants who have failed one prior ARPI treatment, with or without previous taxane chemotherapy exposure. The study has two phases Phase Ib focuses on safety and dosing, and Phase II evaluates preliminary efficacy. The study consists of two phases. Phase Ib includes three dose level groups assessing AMO959 alone first, then combined with AAA617 and ARPI abiraterone or enzalutamide. Dose escalation meetings determine the recommended dose for expansion. Phase II randomizes participants into three arms to receive AMO959 with AAA617 and ARPI, AAA617 with ARPI, or other combinations, with treatments given in cycles up to six times every six weeks. Participants will receive study drugs in scheduled cycles and undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, dose adjustments, drug exposure, and biochemical responses such as PSA levels. Safety and treatment effects are tracked up to approximately 24 to 45 months. The study involves multiple visits for treatment and follow-up evaluations, measuring outcomes like progression-free survival, response rates, and quality of life.
Actively Recruiting
Researchers are evaluating HMBD-001, an anti-HER3 antibody, in combination with cetuximab with or without docetaxel for people with advanced squamous cell cancers. This Phase IbII, open-label, multi-center study focuses on various types of advanced or metastatic squamous cell carcinomas, including lung, head and neck, esophageal, cervical, cutaneous, and nasopharyngeal cancers. The study aims to assess the safety and effectiveness of these treatments in participants who have limited standard care options. Participants receive HMBD-001 intravenously once a week alongside cetuximab weekly, with or without docetaxel administered every three weeks. There are three treatment arms one with HMBD-001 plus docetaxel, one with HMBD-001 plus docetaxel and cetuximab both closed to recruitment, and one with HMBD-001 plus cetuximab. The trial evaluates different combinations to understand their effects on advanced squamous cell cancers. During the study, participants are monitored for adverse events and dose-limiting toxicities. Researchers track progression-free survival up to six months and measure tumor response using established criteria. Blood samples are collected to study the drugs behavior in the body and immune response. The study includes repeated treatment cycles and safety follow-up, with assessments continuing up to 48 months. Participants undergo tumor biopsies and organ function tests to ensure safety and gather comprehensive data.
Actively Recruiting
Researchers are evaluating the safety and preliminary effects of THN391, an investigational drug given as an eye injection, in adults with diabetic macular edema DME caused by non-proliferative diabetic retinopathy. This phase 1b study aims to understand how well THN391 is tolerated and its biological activity in this eye condition. Approximately 21 participants will be enrolled in three groups receiving increasing doses of the drug. Participants will receive three monthly intravitreal injections of THN391 at low, medium, or high doses depending on their assigned group. The study is open-label, meaning everyone knows the dose being given. The treatment period includes these three monthly doses and monitoring for up to 16 weeks after the first dose to assess safety and changes in vision and retinal swelling. During the study, participants will have regular assessments of their eye health including vision tests and retinal examinations. Researchers will track adverse events and measure changes in visual acuity and retinal edema. The total follow-up period lasts up to 16 weeks after the initial dose. The study does not include a placebo group and is designed to carefully monitor safety and biological responses to the drug.
Actively Recruiting
Researchers are evaluating ATG-022 in patients with advanced or metastatic solid tumors in this Phase I, multi-center, open-label clinical trial. The study aims to find the best dose of ATG-022 and to assess its safety and how well it is tolerated. The trial includes patients whose tumors have progressed despite standard treatments or who cannot undergo standard therapies, with a focus on solid tumors and those expressing Claudin 18.2 in the Dose Expansion Phase. The study consists of two main parts a Dose Escalation Phase and a Dose Expansion Phase. In the Dose Escalation Phase, patients receive ATG-022 in cycles of 21 days, starting with a low dose of 0.3 mgkg every three weeks, increasing through defined dose levels to find the maximum tolerated dose. The Dose Expansion Phase enrolls up to 120 patients with Claudin 18.2-positive tumors at the recommended dose to further evaluate safety and efficacy. Participants will undergo biopsies if recent tumor samples are unavailable and must have measurable tumors per RECIST v1.1 criteria. Researchers will monitor side effects and dose-limiting toxicities within 21 days and assess progression-free survival, overall response rate, and duration of response up to 12 months after the last patient is enrolled. Women of childbearing potential and men must use contraception during and after the study. The total participation time varies depending on treatment and follow-up schedules.
1-10 of 50
1